Optometry Australia's chairside reference for the diagnosis and management of age-related macular degeneration.
age-related macular degeneration
chairside reference
diagnosis
imaging
management
optometry
treatment
Journal
Clinical & experimental optometry
ISSN: 1444-0938
Titre abrégé: Clin Exp Optom
Pays: United States
ID NLM: 8703442
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
17
04
2019
revised:
02
07
2019
accepted:
02
08
2019
pubmed:
1
10
2019
medline:
9
6
2021
entrez:
1
10
2019
Statut:
ppublish
Résumé
Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in people over the age of 50 years in Australia. Optometry Australia has developed this AMD chairside reference in consultation with a member-based working group comprised of experienced practitioners. It provides an evidence-based approach to current best practice in the diagnosis and management of AMD. Optometrists should be competent in assessing patients with or at risk of developing AMD, so that they are able to provide evidence-based management including appropriate communication, diagnosis and referral when indicated. This AMD chairside reference covers risk factors for the development of AMD or progression to late-stage AMD; the current clinical classification of AMD; common signs and symptoms; optometric assessment including ocular imaging and biomarkers; differential diagnoses; and management of early, intermediate and late AMD. Optometry Australia's chairside reference is intended as a general guide for optometrists, and is not a formal management protocol.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
254-264Informations de copyright
© 2019 Optometry Australia.
Références
Keel S, Xie J, Foreman J et al. Prevalence of age-related macular degeneration in Australia: the Australian National Eye Health Survey. JAMA Ophthalmol 2017; 135: 1242-1249.
Deloitte Access Economics, Mitchell P. Eyes on the Future: A Clear Outlook on Age-Related Macular Degeneration. Sydney: Macular Degeneration Foundation Australia, 2011.
Flaxman SR, Bourne RRA, Resnikoff S et al. Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis. Lancet Glob Health 2017; 5: e1221-e1234.
Rudnicka AR, Jarrar Z, Wormald R et al. Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis. Ophthalmology 2012; 119: 571-580.
Hassell JB, Lamoureux EL, Keeffe JE. Impact of age related macular degeneration on quality of life. Br J Ophthalmol 2006; 90: 593-596.
Prenner JL, Halperin LS, Rycroft C et al. Disease burden in the treatment of age-related macular degeneration: findings from a time-and-motion study. Am J Ophthalmol 2015; 160: 725-731 e721.
Brody BL, Gamst AC, Williams RA et al. Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration. Ophthalmology 2001; 108: 1893-1901.
Rovner BW, Casten RJ, Tasman WS. Effect of depression on vision function in age-related macular degeneration. Arch Ophthalmol 2002; 120: 1041-1044.
Gopinath B, Kifley A, Cummins R et al. Predictors of psychological distress in caregivers of older persons with wet age-related macular degeneration. Aging Ment Health 2015; 19: 239-246.
Brouwers MC, Kho ME, Browman GP et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ 2010; 182: E839-E842.
Chakravarthy U, Wong TY, Fletcher A et al. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmol 2010; 10: 31.
Klein R, Klein BE, Knudtson MD et al. Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology 2007; 114: 253-262.
Leibowitz HM, Krueger DE, Maunder LR et al. The Framingham Eye Study monograph: an ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. Surv Ophthalmol 1980; 24: 335-610.
Klein ML, Francis PJ, Ferris FL et al. Risk assessment model for development of advanced age-related macular degeneration. Arch Ophthalmol 2011; 129: 1543-1550.
Haddad S, Chen CA, Santangelo SL et al. The genetics of age-related macular degeneration: a review of progress to date. Surv Ophthalmol 2006; 51: 316-363.
Evans JR, Fletcher AE, Wormald RP. 28,000 cases of age related macular degeneration causing visual loss in people aged 75 years and above in the United Kingdom may be attributable to smoking. Br J Ophthalmol 2005; 89: 550-553.
Khan JC, Thurlby DA, Shahid H et al. Smoking and age related macular degeneration: the number of pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularisation. Br J Ophthalmol 2006; 90: 75-80.
Myers CE, Klein BE, Gangnon R et al. Cigarette smoking and the natural history of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology 2014; 121: 1949-1955.
Complications of Age-related Macular Degeneration Prevention Trial Research Group. Risk factors for choroidal neovascularization and geographic atrophy in the complications of age-related macular degeneration prevention trial. Ophthalmology 2008; 115: 1474-1479.
Howard KP, Klein BE, Lee KE et al. Measures of body shape and adiposity as related to incidence of age-related eye diseases: observations from the Beaver Dam Eye Study. Invest Ophthalmol Vis Sci 2014; 55: 2592-2598.
Lechanteur YT, van de Ven JP, Smailhodzic D et al. Genetic, behavioral, and sociodemographic risk factors for second eye progression in age-related macular degeneration. Invest Ophthalmol Vis Sci 2012; 53: 5846-5852.
Seddon JM, Cote J, Davis N et al. Progression of age-related macular degeneration: association with body mass index, waist circumference, and waist-hip ratio. Arch Ophthalmol 2003; 121: 785-792.
van Leeuwen R, Boekhoorn S, Vingerling JR et al. Dietary intake of antioxidants and risk of age-related macular degeneration. JAMA 2005; 294: 3101-3107.
Seddon JM, Cote J, Rosner B. Progression of age-related macular degeneration: association with dietary fat, transunsaturated fat, nuts, and fish intake. Arch Ophthalmol 2003; 121: 1728-1737.
Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA 2013; 309: 2005-2015.
Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001; 119: 1417-1436.
Downie LE, Keller PR. Making sense of the evidence from the age-related eye disease study 2 randomized clinical trial. JAMA Ophthalmol 2014; 132: 1031.
Reynolds R, Rosner B, Seddon JM. Dietary omega-3 fatty acids, other fat intake, genetic susceptibility, and progression to incident geographic atrophy. Ophthalmology 2013; 120: 1020-1028.
Amirul Islam FM, Chong EW, Hodge AM et al. Dietary patterns and their associations with age-related macular degeneration: the Melbourne collaborative cohort study. Ophthalmology 2014; 121: 1428-1434 e1422.
Williams PT. Prospective study of incident age-related macular degeneration in relation to vigorous physical activity during a 7-year follow-up. Invest Ophthalmol Vis Sci 2009; 50: 101-106.
McGuinness MB, Simpson JA, Finger RP. Analysis of the association between physical activity and age-related macular degeneration. JAMA Ophthalmol 2018; 136: 139-140.
National Institute for Health and Care Excellence (NICE). NICE guideline NG82: Age-related macular degeneration. London: NICE, 2018.
Downie LE, Douglass A, Guest D et al. What do patients think about the role of optometrists in providing advice about smoking and nutrition? Ophthalmic Physiol Opt 2017; 37: 202-211.
Ferris FL, Wilkinson CP, Bird A et al. Clinical classification of age-related macular degeneration. Ophthalmology 2013; 120: 844-851.
Ferris FL, Davis MD, Clemons TE et al. A simplified severity scale for age-related macular degeneration: AREDS Report No. 18. Arch Ophthalmol 2005; 123: 1570-1574.
Al-Zamil WM, Yassin SA. Recent developments in age-related macular degeneration: a review. Clin Interv Aging 2017; 12: 1313-1330.
Sadda SR, Guymer R, Holz FG et al. Consensus definition for atrophy associated with age-related macular degeneration on OCT: classification of atrophy report 3. Ophthalmology 2018; 125: 537-548.
Scilley K, Jackson GR, Cideciyan AV et al. Early age-related maculopathy and self-reported visual difficulty in daily life. Ophthalmology 2002; 109: 1235-1242.
Pang L. Hallucinations experienced by visually impaired: Charles Bonnet Syndrome. Optom Vis Sci 2016; 93: 1466-1478.
Finger RP, Wu Z, Luu CD et al. Reticular pseudodrusen: a risk factor for geographic atrophy in fellow eyes of individuals with unilateral choroidal neovascularization. Ophthalmology 2014; 121: 1252-1256.
Joachim N, Mitchell P, Rochtchina E et al. Incidence and progression of reticular drusen in age-related macular degeneration: findings from an older Australian cohort. Ophthalmology 2014; 121: 917-925.
Augustin AJ, Offermann I, Lutz J et al. Comparison of the original Amsler grid with the modified Amsler grid: result for patients with age-related macular degeneration. Retina 2005; 25: 443-445.
Elliott DB. Clinical Procedures in Primary Eye Care, 4th ed. Philadelphia, Pennsylvania: Saunders, 2014.
Ly A, Yapp M, Nivison-Smith L et al. Developing prognostic biomarkers in intermediate age-related macular degeneration: their clinical use in predicting progression. Clin Exp Optom 2018; 101: 172-181.
Wu Z, Luu CD, Ayton LN et al. Optical coherence tomography-defined changes preceding the development of drusen-associated atrophy in age-related macular degeneration. Ophthalmology 2014; 121: 2415-2422.
Bearelly S, Khanifar AA, Lederer DE et al. Use of fundus autofluorescence images to predict geographic atrophy progression. Retina 2011; 31: 81-86.
Holz FG, Bindewald-Wittich A, Fleckenstein M et al. Progression of geographic atrophy and impact of fundus autofluorescence patterns in age-related macular degeneration. Am J Ophthalmol 2007; 143: 463-472.
von Ruckmann A, Fitzke FW, Bird AC. Distribution of fundus autofluorescence with a scanning laser ophthalmoscope. Br J Ophthalmol 1995; 79: 407-412.
Hwang JC, Chan JW, Chang S et al. Predictive value of fundus autofluorescence for development of geographic atrophy in age-related macular degeneration. Invest Ophthalmol Vis Sci 2006; 47: 2655-2661.
Ly A, Nivison-Smith L, Assaad N et al. Infrared reflectance imaging in age-related macular degeneration. Ophthalmic Physiol Opt 2016; 36: 303-316.
Ly A, Nivison-Smith L, Assaad N et al. Fundus autofluorescence in age-related macular degeneration. Optom Vis Sci 2017; 94: 246-259.
Coscas G, Lupidi M, Coscas F et al. Optical coherence tomography angiography during follow-up: qualitative and quantitative analysis of mixed type I and II choroidal neovascularization after vascular endothelial growth factor trap therapy. Ophthalmic Res 2015; 54: 57-63.
Holz FG, Sadda SR, Staurenghi G et al. Imaging protocols in clinical studies in advanced age-related macular degeneration: recommendations from classification of atrophy consensus meetings. Ophthalmology 2017; 124: 464-478.
Royal Australian and New Zealand College of Ophthalmologists. RANZCO Referral Pathway for AMD Screening and Management by Optometrists. 2016. Surry Hills, NSW: RANZCO.
Wu Z, Ayton LN, Luu CD et al. Microperimetry of nascent geographic atrophy in age-related macular degeneration. Invest Ophthalmol Vis Sci 2014; 56: 115-121.
Gass JD. Stereoscopic Atlas of Macular Diseases: Diagnosis and Treatment. C.V. Mosby: St Louis, 1977.
Khan KN, Islam F, Holder GE et al. Normal electrooculography in best disease and autosomal recessive bestrophinopathy. Retina 2018; 38: 379-386.
Weleber RG. Stargardt's macular dystrophy. Arch Ophthalmol 1994; 112: 752-754.
Stone EM, Lotery AJ, Munier FL et al. A single EFEMP1 mutation associated with both Malattia Leventinese and Doyne honeycomb retinal dystrophy. Nat Genet 1999; 22: 199-202.
Fineman MS, Ho AC. Retina: Color Atlas and Synopsis of Clinical Ophthalmology, 2nd ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2012.
Oliver A, Ciulla TA, Comer GM. New and classic insights into presumed ocular histoplasmosis syndrome and its treatment. Curr Opin Ophthalmol 2005; 16: 160-165.
Agarwal A. Gass' Atlas of Macular Diseases. St Louis: Elsevier, 2012.
Chew EY, Clemons TE. Making sense of the evidence from the age-related eye disease study 2 randomized clinical trial-reply. JAMA Ophthalmol 2014; 132: 1031-1032.
National Health and Medical Research Council, Australian Government Department of Health and Ageing, New Zealand Ministry of Health. Nutrient Reference Values for Australia and New Zealand. Canberra: National Health and Medical Research Council, 2006.
Crossland M, Rubin G. The Amsler chart: absence of evidence is not evidence of absence. Br J Ophthalmol 2007; 91: 391-393.
Frisen L. The Amsler grid in modern clothes. Br J Ophthalmol 2009; 93: 714-716.
Luk S, Chen K, Davies N. Variation of online Amsler charts from Google, YouTube and mobile phone Apps. Acta Ophthalmol 2015; 93: e309-e310.
Robison CD, Jivrajka RV, Bababeygy SR et al. Distinguishing wet from dry age-related macular degeneration using three-dimensional computer-automated threshold Amsler grid testing. Br J Ophthalmol 2011; 95: 1419-1423.
Schwartz R, Loewenstein A. Early detection of age related macular degeneration: current status. Int J Retina Vitreous 2015; 1: 20.
Eye Health Council of Ontario. Guidelines for the collaborative management of persons with age-related macular degeneration by health- and eye-care professionals. Can J Optom 2015; 77: 2-11.
Brown DM, Michels M, Kaiser PK et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009; 116: 57-65.
Moshfeghi AA, Rosenfeld PJ, Puliafito CA et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 2002; 2006: e2001-e2012.
Takeda AL, Colquitt J, Clegg AJ et al. Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review. Br J Ophthalmol 2007; 91: 1177-1182.
Rofagha S, Bhisitkul RB, Boyer DS et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 2013; 120: 2292-2299.
Wykoff CC, Croft DE, Brown DM et al. Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results. Ophthalmology 2015; 122: 2514-2522.
Mantel I. Optimizing the anti-VEGF treatment strategy for neovascular age-related macular degeneration: from clinical trials to real-life requirements. Transl Vis Sci Technol 2015; 4: 6.
Finger RP, Guymer RH. Antivascular endothelial growth factor treatments for neovascular age-related macular degeneration save sight, but does everyone get treated? Med J Aust 2013; 198: 260-261.